BOTHELL, WA and VANCOUVER, Feb. 5, 2013 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the following upcoming investor conferences:
- BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 1:00 p.m. ET at the Waldorf Astoria Hotel in New York City
- Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 2:30 p.m. ET at the Waldorf Astoria Hotel in New York City
- RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at 11:30 a.m. ET at the New York Palace Hotel in New York City
Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. Webcast replays will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com
SOURCE: OncoGenex Pharmaceuticals, Inc.
For further information:
Investor Relations Contact: